The sequential improvement in gross margin from 61.4% to 66.0% over six quarters suggests that Haleon is successfully executing on its standalone cost optimization, likely benefiting from supply chain efficiencies and a favorable product mix. Operating margin expansion to 23.8% in 2026Q2, up from 19.0% in 2024Q4, indicates that the company is leveraging its fixed cost base more effectively, with SG&A growth lagging gross profit gains. This margin trajectory appears sustainable given the company's focus on high-margin Power Brands, though investors should monitor whether the 22.44% operating margin can be maintained without the shared infrastructure of former parents.

The upward trend in ROIC from 1.4% in 2022Q4 to 4.3% in 2026Q2 reflects both margin expansion and improved asset turnover, which has stabilized at 0.17x. However, the absolute level of ROIC remains modest, partly due to the large goodwill base from the demerger, which inflates invested capital. The improvement in ROE to 4.7% from 1.6% over the same period suggests that the company is beginning to generate returns above its cost of capital, but the pace of improvement may be constrained by the need to service debt and the ongoing share overhang.

The negative cash conversion cycle indicates that Haleon is effectively using supplier financing, with DPO extending to 179 days in 2026Q2 from 119 days in 2024Q4, while DSO remained stable around 36 days. This suggests strong bargaining power over suppliers, likely due to its scale and brand portfolio. The improvement in CCC from -29 to -93 days over six quarters implies that working capital is a source of cash, supporting free cash flow generation. However, the extended payables may strain supplier relationships if not managed carefully, and the seasonal swings in working capital, as seen in the prior cash flow analysis, warrant monitoring.

The significant reduction in D/EBITDA from 17.01 in 2022Q4 to 5.41 in 2026Q2 indicates that Haleon has made substantial progress in reducing its debt burden relative to earnings, likely through a combination of debt repayment and EBITDA growth. Interest coverage has improved to 8.73 from 7.11 over the same period, suggesting that debt service is becoming more comfortable. However, the current ratio of 0.69 and quick ratio of 0.52 in 2026Q2 highlight a tight liquidity position, with cash of only $821M, which may limit flexibility in the face of seasonal working capital needs or unexpected expenses.

The current ratio has deteriorated from 1.04 in 2023Q4 to 0.69 in 2026Q2, suggesting that current liabilities exceed current assets, which is typical for companies with strong supplier financing but also indicates limited short-term buffer. The quick ratio of 0.52 in 2026Q2, down from 0.71 in 2025Q4, further underscores the reliance on inventory and receivables to cover near-term obligations. While the negative cash conversion cycle provides some comfort, the thin cash position of $821M may not be sufficient to absorb a significant operational shock, such as a major regulatory fine or a sharp downturn in respiratory sales.